Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Anteris Technologies is an Australian medical device company developing structural heart solutions, primarily focused on its DurAVR transcatheter aortic valve replacement (TAVR) system featuring proprietary ADAPT anti-calcification tissue technology. The company is pre-revenue, currently in clinical trial phases across multiple geographies including US IDE trials and European CE Mark studies, positioning for commercialization in the $7+ billion global TAVR market dominated by Edwards Lifesciences and Medtronic.
Anteris is developing a differentiated TAVR valve using ADAPT tissue technology designed to resist calcification and extend durability beyond current 10-15 year benchmarks. Revenue model will be per-unit device sales to hospitals and cardiac centers, with pricing expected in the $25,000-35,000 range per valve consistent with market leaders. Competitive advantage hinges on demonstrating superior long-term durability data that could expand TAVR to younger patient populations (currently limited to 65+ years due to durability concerns). Company must complete pivotal trials, secure FDA approval and CE Mark, then build commercial infrastructure or partner for distribution.
Clinical trial enrollment milestones and interim data readouts from US IDE pivotal trial and European studies
Regulatory progress - FDA breakthrough device designation updates, IDE approval stages, CE Mark submission timing
Capital raises and cash runway visibility given -$8M quarterly burn rate and 0.84x current ratio
Partnership or licensing announcements for ADAPT technology or commercial distribution rights
Competitive TAVR durability data from Edwards/Medtronic that validates or challenges Anteris's differentiation thesis
Binary regulatory risk - FDA may require larger trial sizes, longer follow-up periods, or reject approval if durability/safety endpoints not met, potentially adding 2-4 years and $50-100M in costs
Reimbursement uncertainty - CMS and private payers must establish favorable coverage policies for DurAVR; inadequate reimbursement rates could limit commercial viability despite FDA approval
Technology obsolescence risk - next-generation TAVR systems, alternative structural heart therapies, or improved surgical techniques could diminish market opportunity before Anteris reaches commercialization
Edwards Lifesciences (80% market share) and Medtronic dominate with established clinical data, physician relationships, and continuous product iteration - extremely high barriers for new entrants to gain meaningful share
Larger competitors developing their own next-generation durability solutions with vastly superior resources for clinical trials, manufacturing scale, and commercial infrastructure
Physician adoption inertia - cardiac surgeons trained on incumbent systems reluctant to switch absent compelling 5+ year durability data that Anteris cannot provide until years post-launch
Critical liquidity risk - 0.84x current ratio and -$8M quarterly cash burn implies 6-9 month runway requiring imminent capital raise, likely highly dilutive at current $200M market cap
Debt/equity of 0.64x manageable in absolute terms but concerning given no revenue to service obligations; likely convertible notes that could force dilution
Negative equity ROE of -251% reflects accumulated losses of $45M+ against small equity base; requires $200M+ additional capital to reach commercialization based on typical medtech development costs
low - As a pre-revenue clinical-stage company, Anteris is insulated from economic cycles affecting device sales. However, hospital capital budgets for new technology adoption post-approval could face pressure in recessions. Primary sensitivity is to biotech funding cycles and risk appetite for clinical-stage assets rather than GDP growth.
Rising rates negatively impact valuation through higher discount rates applied to distant future cash flows (estimated commercialization 2027-2028). Clinical-stage medtech trades at 8-12x forward revenue multiples, highly sensitive to risk-free rate changes. Higher rates also increase cost of capital for future financing rounds, potentially forcing more dilutive equity raises. Debt financing unavailable at this stage given negative cash flow.
Minimal direct credit exposure. Company relies on equity financing rather than debt markets given pre-revenue status. Indirect exposure through hospital purchasing patterns - tighter credit conditions could delay hospital adoption of premium-priced new technologies post-launch, but structural heart procedures are largely non-discretionary.
growth/speculative - Attracts high-risk biotech investors seeking asymmetric returns from successful clinical development and regulatory approval. 65% three-month return suggests momentum traders active on clinical milestones. Negative margins and pre-revenue status eliminate value and income investors. Requires 3-5 year investment horizon and tolerance for binary outcomes and significant dilution risk. Typical holders include specialized healthcare funds, Australian biotech investors, and retail speculators.
high - Clinical-stage medtech exhibits extreme volatility around trial data releases, regulatory decisions, and financing events. Limited liquidity at $200M market cap amplifies price swings. 65% three-month gain followed by -33% one-year return demonstrates boom-bust pattern typical of binary clinical catalysts. Estimated beta 1.8-2.2x versus healthcare sector given pre-revenue risk profile.
